BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2021.07.07.21260124: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Serological analysis: SARS-CoV-2–specific IgG antibodies were measured as previously described [28]. SARS-CoV-2–specific IgGsuggested: NoneThe panel is designed to detect antibodies to five SARS-CoV-2 antigens: nucleocapsid, spike S1 Receptor Binding Domain (RBD), spike S1S2, spike S2, and spike S1, within a multiplex format based on photonic ring resonance technology. antigens: nucleocapsid , spike S1 Receptor Binding Domain ( RBDsuggested: NoneThe chip was then washed to remove … SciScore for 10.1101/2021.07.07.21260124: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Serological analysis: SARS-CoV-2–specific IgG antibodies were measured as previously described [28]. SARS-CoV-2–specific IgGsuggested: NoneThe panel is designed to detect antibodies to five SARS-CoV-2 antigens: nucleocapsid, spike S1 Receptor Binding Domain (RBD), spike S1S2, spike S2, and spike S1, within a multiplex format based on photonic ring resonance technology. antigens: nucleocapsid , spike S1 Receptor Binding Domain ( RBDsuggested: NoneThe chip was then washed to remove low-affinity binders, and specific antibodies were detected with anti-IgG secondary antibodies. anti-IgGsuggested: NoneC, anti-IgD FITC, anti-CD38 PerCPCy5.5, CD27 PE-Cy7, CD24 APC-H7, CD86 PE, CD3 BV421, CD14 BV421, CD21 BV421 lyophilized antibodies (BD Horizon™ Lyo technology). anti-IgD FITCsuggested: Noneanti-CD38suggested: NoneCD27suggested: NoneCD3suggested: NoneCD14suggested: NoneCD21suggested: (BD Biosciences Cat# 562966, RRID:AB_2737921)Experimental Models: Cell Lines Sentences Resources Pseudoneutralization assay: Lentiviral particles carrying the luciferase gene and pseudotyped with spikes of SARS-CoV-2 historical strain or VOCs were produced by triple transfection of 293T cells as previously described [28]. 293Tsuggested: CCLV Cat# CCLV-RIE 1018, RRID:CVCL_0063)This mixture was then plated on tissue culture–treated black 96-well plates (Costar) with 20,000 HEK 293T-hACE2 cells per well in suspension. HEK 293T-hACE2suggested: NoneSoftware and Algorithms Sentences Resources Cells were acquired on a BD FACS Canto II flow cytometer (BD Biosciences) and analyzed with FlowJo v10 software (FlowJo, LLC) according to the gating strategy presented in Figure S1. FlowJosuggested: (FlowJo, RRID:SCR_008520)Statistical analysis was performed using R software (version 4.1.0) and GraphPad Prism software, V6 (GraphPad, San Diego). GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)GraphPadsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Our study has some limitations. It is surprising to note that SARS-CoV-2-specific T cell responses were detected in only 57% of patients who had neutralizing antibody titers. This observation questions the sensitivity of the QTF assay used in our study and another [51]. Future studies should include other assays such T cell ELISPOT[52] to confirm this observation and whether low T cell responses would be more likely associated with SLE, compared to other RMDs and to healthy controls. Moreover, QTF assay was performed 15 days after the second dose, a timing that may be too short to optimally detect SARS-CoV-2 specific T cell response. Longitudinal studies are thus required to determine whether SLE patients develop a delayed cellular immune response. Unlike previous authors [3–5], we did not use antibody-response positivity thresholds. There are, however, no studies showing that these thresholds give RMD patients real protection against the risk of subsequent infection with SARS-CoV-2. It is not yet clear as to what immunogenicity parameter is predictive of vaccine-induced protection. Additionally, these thresholds vary according to the assays used and the variants studied, their clinical relevance is therefore questionable. To address this issue, Khoury et al. [53] recently analyzed the relationship between in vitro neutralization levels and the observed protection from SARS-CoV-2 infection using data from seven current vaccines and from convalescent cohorts. These authors fou...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
